Panbela Therapeutics, Inc.
PBLA · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $7,165 | $8,103 | $6,726 | $7,047 |
| Gross Profit | -$7,165 | -$8,103 | -$6,726 | -$7,047 |
| % Margin | – | – | – | – |
| R&D Expenses | $6,052 | $6,997 | $5,522 | $6,113 |
| G&A Expenses | $1,113 | $1,106 | $1,204 | $931 |
| SG&A Expenses | $1,113 | $1,106 | $1,204 | $931 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7,165 | $8,103 | $6,726 | $7,044 |
| Operating Income | -$14,330 | -$8,103 | -$6,726 | -$7,044 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $7,158 | $964 | -$532 | $551 |
| Pre-Tax Income | -$7,172 | -$7,139 | -$7,258 | -$6,493 |
| Tax Expense | $0 | $0 | -$138 | -$19 |
| Net Income | -$7,172 | -$7,139 | -$7,120 | -$6,474 |
| % Margin | – | – | – | – |
| EPS | -1.48 | -1.47 | -2.28 | -0.027 |
| % Growth | -0.7% | 35.5% | -8,251.6% | – |
| EPS Diluted | -1.48 | -1.47 | -2.28 | -0.027 |
| Weighted Avg Shares Out | 4,855 | 4,855 | 3,126 | 237,234 |
| Weighted Avg Shares Out Dil | 4,855 | 4,855 | 3,126 | 237,234 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $9 |
| Interest Expense | $442 | $59 | $63 | $72 |
| Depreciation & Amortization | $0 | $1,023 | $0 | $0 |
| EBITDA | -$6,730 | -$6,057 | -$7,195 | -$6,421 |
| % Margin | – | – | – | – |